by barry-jtcir | Sep 6, 2023 | Press Releases
LA JOLLA, CA, Sept. 06, 2023 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory,...
by barry-jtcir | Sep 1, 2023 | Press Releases
LA JOLLA, CA / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but it is believed to involve a...
by barry-jtcir | Aug 25, 2023 | Press Releases
LA JOLLA, CA / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body’s immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are...
by barry-jtcir | Aug 23, 2023 | Press Releases
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation technology for certain follow-on pipeline programs in development GRI to...
by barry-jtcir | Aug 14, 2023 | Press Releases
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023 Ongoing progress towards completion of...
